{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:15:33Z","timestamp":1793682933493,"version":"4.5.1"},"reference-count":155,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"2","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2024,2,21]]},"DOI":"10.1167\/iovs.65.2.30","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T11:31:14Z","timestamp":1708515074000},"page":"30","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Nintedanib and Anti-Angiogenic Agents on Uveal Melanoma Cell Behavior"],"prefix":"10.1167","volume":"65","author":[{"given":"Vera E.","family":"Pawlik","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja R.","family":"Sonntag","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayseg\u00fcl","family":"Tura","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinodh","family":"Kakkassery","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdy","family":"Ranjbar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"issue":"7","key":"bib1","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/IAE.0b013e31824d09a8","article-title":"Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases","volume":"32","author":"Shields","year":"2012","journal-title":"Retina"},{"issue":"12","key":"bib2","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ophtha.2007.01.032","article-title":"Incidence of uveal melanoma in Europe","volume":"114","author":"Virgili","year":"2007","journal-title":"Ophthalmology"},{"issue":"9","key":"bib3","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"issue":"1","key":"bib4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ohc.2004.07.002","article-title":"Uveal melanoma: epidemiologic aspects","volume":"18","author":"Singh","year":"2005","journal-title":"Ophthalmol Clin North Am"},{"issue":"1","key":"bib5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijrobp.2005.01.058","article-title":"Effectiveness of fractionated stereotactic radiotherapy for uveal melanoma","volume":"63","author":"Muller","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"bib6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brachy.2013.11.008","article-title":"The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma","volume":"13","author":"Simpson","year":"2014","journal-title":"Brachytherapy"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2147\/OPTH","article-title":"Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions","volume":"12","author":"Brewington","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"bib8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.4103\/0974-9233.65494","article-title":"Exoresection and endoresection for uveal melanoma","volume":"17","author":"G\u00fcnd\u00fcz","year":"2010","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"3","key":"bib9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0002-9394(98)00091-9","article-title":"The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma III: local complications and observations following enucleation COMS report no. 11","volume":"126","author":"Collaborative Ocular Melanoma Study Group","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"bib10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0161-6420(85)34019-8","article-title":"The role of orbital exenteration in choroidal melanoma with extrascleral extension","volume":"92","author":"Kersten","year":"1985","journal-title":"Ophthalmology"},{"issue":"3","key":"bib11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/02841860500468950","article-title":"Visual outcome, local tumour control, and eye preservation after 106Ru\/Rh brachytherapy for choroidal melanoma","volume":"45","author":"Isager","year":"2006","journal-title":"Acta Oncol"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"bib13","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no. 26","volume":"123","author":"Diener-West","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"bib14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1158\/1078-0432.CCR-06-2630","article-title":"Molecular pathways mediating liver metastasis in patients with uveal melanoma","volume":"14","author":"Bakalian","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"bib15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.humpath.2017.06.005","article-title":"Inflammatory cell infiltrates in advanced metastatic uveal melanoma","volume":"66","author":"Krishna","year":"2017","journal-title":"Human Pathol"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"175883592311601","DOI":"10.1177\/17588359231160140","article-title":"Tebentafusp: a first-in-class treatment f or metastatic uveal melanoma","volume":"15","author":"Howlett","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"bib18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nrc909","article-title":"VEGF and the quest for tumour angiogenesis factors","volume":"2","author":"Ferrara","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"bib19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00000658-197203000-00014","article-title":"Anti-angiogenesis: new concept for therapy of solid tumors","volume":"175","author":"Folkman","year":"1972","journal-title":"Ann Surg"},{"issue":"6","key":"bib20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3390\/cancers11060834","article-title":"Uveal melanoma, angiogenesis and immunotherapy, is there any hope?","volume":"11","author":"Castet","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7","key":"bib21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/jnci\/87.7.506","article-title":"Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma","volume":"87","author":"Boocock","year":"1995","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"bib22","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1182\/blood.V98.6.1904","article-title":"Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor\u2013positive human tumors","volume":"98","author":"Masood","year":"2001","journal-title":"Blood"},{"issue":"10","key":"bib23","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1097\/00005537-200110000-00031","article-title":"Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck","volume":"111","author":"Neuchrist","year":"2001","journal-title":"Laryngoscope"},{"issue":"54","key":"bib24","doi-asserted-by":"publisher","first-page":"8025","DOI":"10.1038\/sj.onc.1208939","article-title":"Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid","volume":"24","author":"Gee","year":"2005","journal-title":"Oncogene"},{"issue":"4","key":"bib25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0022-5347(05)00736-6","article-title":"Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer","volume":"175","author":"Xia","year":"2006","journal-title":"J Urol"},{"issue":"6","key":"bib26","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1371\/journal.pmed.0040186","article-title":"Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1\/FLT1. Kerbel RS, Herausgeber","volume":"4","author":"Lee","year":"2007","journal-title":"PLoS Med"},{"issue":"10","key":"bib27","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1158\/1541-7786.MCR-07-2172","article-title":"An autocrine VEGF\/VEGFR2 and p38 signaling loop confers resistance to 4- hydroxytamoxifen in MCF-7 breast cancer cells","volume":"6","author":"Aesoy","year":"2008","journal-title":"Mol Cancer Res"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000224877","article-title":"Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer","volume":"83","author":"Nakanishi","year":"2009","journal-title":"Urol Int"},{"issue":"12","key":"bib29","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1248\/bpb.34.1785","article-title":"Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy","volume":"34","author":"Takahashi","year":"2011","journal-title":"Biol Pharm Bull"},{"issue":"7","key":"bib30","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1593\/neo.11948","article-title":"The effect of bevacizumab on human malignant melanoma cells with functional VEGF\/VEGFR2 autocrine and intracrine signaling loops","volume":"14","author":"Adamcic","year":"2012","journal-title":"Neoplasia"},{"issue":"4","key":"bib31","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1172\/JCI65385","article-title":"Tumor VEGF:VEGFR2 autocrine feed- forward loop triggers angiogenesis in lung cancer","volume":"123","author":"Chatterjee","year":"2013","journal-title":"J Clin Invest"},{"issue":"6","key":"bib32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/bjc.2017.238","article-title":"Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion","volume":"117","author":"Bhattacharya","year":"2017","journal-title":"Br J Cancer"},{"issue":"6","key":"bib34","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/cancers11060846","article-title":"Targeted therapy of uveal melanoma: recent failures and new perspectives","volume":"11","author":"Croce","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"9","key":"bib35","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"bib36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/(ISSN)1096-9896","article-title":"Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours","volume":"186","author":"Stitt","year":"1998","journal-title":"J Pathol"},{"issue":"5","key":"bib37","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1167\/iovs.09-4739","article-title":"Regulation of VEGF-A in uveal melanoma","volume":"51","author":"el Filali","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"bib38","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1167\/iovs.09-4755","article-title":"Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma","volume":"51","author":"Yang","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib39","first-page":"2454","article-title":"Bevacizumab and intraocular tumors: an intriguing paradox","volume":"18","author":"el Filali","year":"2012","journal-title":"Mol Vis"},{"issue":"3","key":"bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5693\/djo.02.2020.06.001","article-title":"Rapid growth of primary uveal melanoma following intravitreal bevacizumab injection: a case report and review of the literature","volume":"26","author":"Ma","year":"2020","journal-title":"Digit J Ophthalmol. 3."},{"issue":"2","key":"bib41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000450859","article-title":"Growth of uveal melanoma following intravitreal bevacizumab","volume":"3","author":"Francis","year":"2017","journal-title":"Ocul Oncol Pathol"},{"issue":"1","key":"bib42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2174\/1874364101610010103","article-title":"Serial intravitreal bevacizumab injections slow the progression of radiation maculopathy following iodine-125 plaque radiotherapy","volume":"10","author":"Stacey","year":"2016","journal-title":"Open Ophthalmol J"},{"issue":"5","key":"bib43","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/00008390-199910000-00003","article-title":"Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines","volume":"9","author":"Ijland","year":"1999","journal-title":"Melanoma Res"},{"issue":"9","key":"bib44","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/02713680600865052","article-title":"Angiogenic profile of uveal melanoma","volume":"31","author":"Notting","year":"2006","journal-title":"Curr Eye Res"},{"issue":"1","key":"bib45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2741\/e60","article-title":"CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression","volume":"2","author":"Franco","year":"2010","journal-title":"Front Biosci (Elite Ed)"},{"issue":"4","key":"bib46","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1167\/iovs.13-13254","article-title":"Autocrine impact of VEGF-A on uveal melanoma cells","volume":"55","author":"Koch","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"bib47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/aos.2013.91.issue-4","article-title":"Disseminated tumour cells in bone marrow of patients with uveal melanoma","volume":"91","author":"Eide","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"bib48","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"issue":"5","key":"bib49","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"bib50","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"bib51","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"issue":"14","key":"bib52","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1021\/jm900431g","article-title":"Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6- methoxycarbonyl-substituted indolinone (BIBF 1120)","volume":"52","author":"Roth","year":"2009","journal-title":"J Med Chem"},{"issue":"5","key":"bib53","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1586\/14737140.2015.1031218","article-title":"Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor","volume":"15","author":"Reck","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"bib54","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1023\/A:1018479011340","article-title":"Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease","volume":"15","author":"Chen","year":"1996","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"bib55","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/(ISSN)1097-0215","article-title":"Melanomas that develop within the eye inhibit lymphocyte proliferation","volume":"73","author":"Verbik","year":"1997","journal-title":"Int J Cancer"},{"issue":"4","key":"bib56","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: building a framework","volume":"127","author":"Gupta","year":"2006","journal-title":"Cell"},{"key":"bib57","first-page":"T5(1-16)","article-title":"Uveal melanoma cell lines: where do they come from? (An American Ophthalmological Society Thesis)","volume":"114","author":"Jager","year":"2016","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"3","key":"bib58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000370150","article-title":"Culturing uveal melanoma cells","volume":"1","author":"Angi","year":"2015","journal-title":"Ocul Oncol Pathol"},{"issue":"14","key":"bib59","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0959-8049(99)00292-0","article-title":"Control of the cell cycle and apoptosis","volume":"35","author":"Lundberg","year":"1999","journal-title":"Eur J Cancer"},{"issue":"3","key":"bib62","first-page":"216","article-title":"Cytotoxicity of dimethyl sulphoxide on ocular cells in vitro","volume":"33","author":"Zhao","year":"2015","journal-title":"Chin J Ophthalmol"},{"issue":"1","key":"bib63","first-page":"e33453","article-title":"Cytotoxic effects of some common organic solvents on MCF-7, RAW-264.7 and human umbilical vein endothelial cells","volume":"4","author":"Jamalzadeh","year":"2016","journal-title":"Avicenna J Med Biochem"},{"issue":"1\u20132","key":"bib64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"issue":"2","key":"bib65","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","article-title":"Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability","volume":"89","author":"Denizot","year":"1986","journal-title":"J Immunol Methods"},{"issue":"3","key":"bib66","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/bjc.1987.190","article-title":"A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity","volume":"56","author":"Twentyman","year":"1987","journal-title":"Br J Cancer"},{"issue":"1","key":"bib69","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0022-1759(90)90322-M","article-title":"New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy","volume":"133","author":"Weston","year":"1990","journal-title":"J Immunol Methods"},{"issue":"1","key":"bib70","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0022-1759(94)90384-0","article-title":"Use of fluorescent dyes in the determination of adherence of human leucocytes to endothelial cells and the effect of fluorochromes on cellular function","volume":"172","author":"De Clerck","year":"1994","journal-title":"J Immunol Methods"},{"issue":"3","key":"bib71","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/molecules26030615","article-title":"Anticancer activity of the acetylenic derivative of betulin phosphate involves induction of necrotic-like death in breast cancer cells in vitro","volume":"26","author":"Orchel","year":"2021","journal-title":"Molecules"},{"issue":"7","key":"bib72","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"issue":"20","key":"bib74","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"bib75","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1136\/bjophthalmol-2014-305302","article-title":"Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture","volume":"98","author":"Malik","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"bib76","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2147\/DDDT","article-title":"Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib","volume":"11","author":"Lin","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"1\u20132","key":"bib77","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0022-1759(86)90215-2","article-title":"Use of MTT colorimetric assay to measure cell activation","volume":"94","author":"Gerlier","year":"1986","journal-title":"J Immunol Methods"},{"issue":"6","key":"bib78","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/bjc.1988.125","article-title":"Chemosensitivity testing of human lung cancer cell lines using the MTT assay","volume":"57","author":"Carmichael","year":"1985","journal-title":"Br J Cancer"},{"issue":"3","key":"bib79","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF00256695","article-title":"Rapid chemosensitivity testing of human lung tumor cells using the MTT assay","volume":"17","author":"Cole","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"bib80","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/0277-5379(86)90162-8","article-title":"Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines","volume":"22","author":"Finlay","year":"1986","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"22","key":"bib81","first-page":"5875","article-title":"Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetrie assay","volume":"47","author":"Park","year":"1987","journal-title":"Cancer Res"},{"issue":"3","key":"bib82","first-page":"589","article-title":"Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay","volume":"48","author":"Alley","year":"1988","journal-title":"Cancer Res"},{"issue":"5","key":"bib83","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF00304761","article-title":"Comparison of tetrazolium colorimetric and [3H]- uridine assays for in vitro chemosensitivity testing","volume":"24","author":"Ford","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"bib84","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0022-1759(84)90190-X","article-title":"Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines","volume":"70","author":"Green","year":"1984","journal-title":"J Immunol Methods"},{"issue":"1","key":"bib85","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/bjc.1991.16","article-title":"Chemosensitivity testing of small cell lung cancer using the MTT assay","volume":"63","author":"Campling","year":"1991","journal-title":"Br J Cancer"},{"issue":"1","key":"bib86","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13046-017-0592-3","article-title":"Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer","volume":"36","author":"Englinger","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"bib87","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3390\/cancers11060868","article-title":"Uptake of ranibizumab but not bevacizumab into uveal melanoma cells correlates with a sustained decline in VEGF-A levels and metastatic activities","volume":"11","author":"Tura","year":"2019","journal-title":"Cancers"},{"issue":"5","key":"bib88","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/01.iae.0000222547.35820.52","article-title":"Evaluation of in vitro effects of bevacizumab (avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells","volume":"26","author":"Luthra","year":"2006","journal-title":"Retina"},{"issue":"6","key":"bib89","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1089\/jop.2009.0028","article-title":"Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor\u2013enriched choroidal endothelial cells","volume":"25","author":"Brar","year":"2009","journal-title":"J Oncul Pharmacol Ther"},{"issue":"7","key":"bib90","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1136\/bjophthalmol-2013-303130","article-title":"Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells","volume":"97","author":"Schnichels","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"31","key":"bib91","doi-asserted-by":"publisher","first-page":"8136","DOI":"10.1200\/JCO.2005.02.5635","article-title":"Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients","volume":"23","author":"Willett","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"bib92","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1158\/0008-5472.CAN-07-6577","article-title":"Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity","volume":"68","author":"Kawamura","year":"2008","journal-title":"Cancer Res"},{"issue":"7","key":"bib93","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/sj.bjc.6604309","article-title":"The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice","volume":"98","author":"Rennel","year":"2008","journal-title":"Br J Cancer"},{"issue":"8","key":"bib94","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1158\/0008-5472.CAN-14-1855","article-title":"Induction of vasculogenic mimicry overrides VEGF-A silencing and enriches stem-like cancer cells in melanoma","volume":"75","author":"Schnegg","year":"2015","journal-title":"Cancer Res"},{"issue":"2","key":"bib95","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.canlet.2005.01.002","article-title":"The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells","volume":"226","author":"Kapitza","year":"2005","journal-title":"Cancer Lett"},{"issue":"7","key":"bib96","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"bib97","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/10715762.2011.645207","article-title":"Mitochondrial dysfunction, a probable cause of persistent oxidative stress after exposure to ionizing radiation","volume":"46","author":"Yoshida","year":"2012","journal-title":"Free Radic Res"},{"issue":"12","key":"bib98","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"bib99","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/2049-3002-2-17","article-title":"Mitochondrial reactive oxygen species and cancer","volume":"2","author":"Sullivan","year":"2014","journal-title":"Cancer Metab"},{"issue":"1","key":"bib100","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13046-018-0909-x","article-title":"The role of cellular reactive oxygen species in cancer chemotherapy","volume":"37","author":"Yang","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"bib101","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10495-007-0756-2","article-title":"Mitochondria, oxidative stress and cell death","volume":"12","author":"Ott","year":"2007","journal-title":"Apoptosis"},{"issue":"2","key":"bib102","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0955-0674(98)80147-6","article-title":"Oxygen radicals and signaling","volume":"10","author":"Finkel","year":"1998","journal-title":"Curr Opin Cell Biol"},{"key":"bib103","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.canlet.2019.03.020","article-title":"Reactive oxygen species and cancer: a complex interaction","volume":"452","author":"Saikolappan","year":"2019","journal-title":"Cancer Lett"},{"issue":"5","key":"bib104","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/01902148.2020.1738594","article-title":"Anti-oxidative effect of the tyrosine kinase inhibitor nintedanib: a potential therapy for chronic lung allograft dysfunction?","volume":"46","author":"Boxhammer","year":"2020","journal-title":"Exp Lung Res"},{"issue":"1","key":"bib105","doi-asserted-by":"publisher","first-page":"C345","DOI":"10.1152\/ajpcell.00216.2007","article-title":"Regulation of fibroblast growth factor-2 expression in pulmonary arterial smooth muscle cells involves increased reactive oxygen species generation","volume":"294","author":"Black","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"bib106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/654594","article-title":"Transforming growth factor-beta and oxidative stress interplay: implications in tumorigenesis and cancer progression","volume":"2015","author":"Krstic","year":"2015","journal-title":"Oxid Med Cellul Longev"},{"issue":"6","key":"bib107","doi-asserted-by":"publisher","first-page":"L1005","DOI":"10.1152\/ajplung.2000.279.6.L1005","article-title":"Reactive oxygen species in cell signaling","volume":"279","author":"Thannickal","year":"2000","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"bib108","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000047804","article-title":"Reactive oxygen species as intracellular messengers during cell growth and differentiation","volume":"11","author":"Sauer","year":"2001","journal-title":"Cell Physiol Biochem"},{"issue":"41","key":"bib109","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.2174\/1381612821666151029111127","article-title":"Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase","volume":"21","author":"Chan","year":"2015","journal-title":"Curr Pharm Des"},{"issue":"16","key":"bib110","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1242\/jcs.195966","article-title":"Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration","volume":"129","author":"El-Remessy","year":"2016","journal-title":"J Cell Sci"},{"issue":"6","key":"bib111","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1089\/ars.2007.1989","article-title":"Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension","volume":"10","author":"Schulz","year":"2008","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"bib112","doi-asserted-by":"publisher","first-page":"e94540","DOI":"10.1371\/journal.pone.0094540","article-title":"Vascular endothelial growth factor-receptor 1 inhibition aggravates diabetic nephropathy through eNOS signaling pathway in db\/db mice","volume":"9","author":"Yang","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"bib113","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1111\/aos.2015.93.issue-8","article-title":"Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell","volume":"93","author":"Sheu","year":"2015","journal-title":"Acta Ophthalmologica"},{"key":"bib114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exer.2017.04.005","article-title":"Cellular stress response in human M\u00fcller cells (MIO-M1) after bevacizumab treatment","volume":"160","author":"Matsuda","year":"2017","journal-title":"Exp Eye Res"},{"issue":"1","key":"bib115","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0041-008X(90)90278-3","article-title":"Organometal-induced increases in oxygen reactive species: the potential of 2',7'-dichlorofluorescin diacetate as an index of neurotoxic damage","volume":"104","author":"LeBel","year":"1990","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"bib116","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/0006-2952(91)90048-A","article-title":"Effects of toluene and its metabolites on cerebral reactive oxygen species generation","volume":"42","author":"Mattia","year":"1991","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"bib117","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0041-008X(92)90292-Z","article-title":"Deferoxamine inhibits methyl mercury-induced increases in reactive oxygen species formation in rat brain","volume":"112","author":"LeBel","year":"1992","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"bib118","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1021\/tx00026a012","article-title":"Evaluation of the probe 2\u2019,7\u2019-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress","volume":"5","author":"LeBel","year":"1992","journal-title":"Chem Res Toxicol"},{"issue":"10","key":"bib119","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1006\/cbir.2000.0556","article-title":"2,7-dichlorofluorescin oxidation and reactive oxygen species: what does it measure?","volume":"24","author":"Jakubowski","year":"2000","journal-title":"Cell Biol Int"},{"issue":"7239","key":"bib120","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/nature07733","article-title":"Association of reactive oxygen species levels and radioresistance in cancer stem cells","volume":"458","author":"Diehn","year":"2009","journal-title":"Nature"},{"issue":"2","key":"bib121","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1167\/iovs.15-18245","article-title":"Vascular endothelial growth factor (VEGF) concentration is underestimated by enzyme- linked immunosorbent assay in the presence of anti-VEGF drugs","volume":"57","author":"Takahashi","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"bib122","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.yexcr.2010.12.014","article-title":"Quantification and cell-to-cell variation of vascular endothelial growth factor receptors","volume":"317","author":"Imoukhuede","year":"2011","journal-title":"Exp Cell Res"},{"issue":"6","key":"bib123","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.2144\/01306st02","article-title":"RT-PCR method to quantify vascular endothelial growth factor expression","volume":"30","author":"Bonino","year":"2001","journal-title":"BioTechniques"},{"issue":"20","key":"bib124","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-04-1750","article-title":"Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death","volume":"64","author":"Onken","year":"2004","journal-title":"Cancer Res"},{"issue":"2","key":"bib125","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"issue":"5","key":"bib126","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10384-007-0456-z","article-title":"Expression of vascular endothelial growth factor-a, matrix metalloproteinase-9, and extravascular matrix patterns and their correlations with clinicopathologic parameters in posterior uveal melanomas","volume":"51","author":"Sahin","year":"2007","journal-title":"Jpn J Ophthalmol"},{"issue":"15","key":"bib127","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.4161\/cc.5.15.3112","article-title":"Stromal fibroblasts in cancer: a novel tumor-promoting cell type","volume":"5","author":"Orimo","year":"2006","journal-title":"Cell Cycle"},{"issue":"8","key":"bib128","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.yexcr.2010.02.045","article-title":"Hallmarks of cancer: interactions with the tumor stroma","volume":"316","author":"Pietras","year":"2010","journal-title":"Exp Cell Res"},{"issue":"7","key":"bib129","first-page":"1414","article-title":"Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma","volume":"42","author":"M\u00e4kitie","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"bib130","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1167\/iovs.07-0786","article-title":"Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma","volume":"49","author":"Maat","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"bib131","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1167\/iovs.10-5979","article-title":"Detection of M2-macrophages in uveal melanoma and relation with survival","volume":"52","author":"Bronkhorst","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"bib132","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41416-020-01201-z","article-title":"Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts","volume":"124","author":"Kato","year":"2021","journal-title":"Br J Cancer"},{"issue":"3","key":"bib133","doi-asserted-by":"publisher","first-page":"e15295","DOI":"10.15252\/emmm.202115295","article-title":"Blockade of the pro-fibrotic reaction mediated by the miR-143\/-145 cluster enhances the responses to targeted therapy in melanoma","volume":"14","author":"Diazzi","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"7","key":"bib134","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/pharmaceutics13071005","article-title":"Development of dual ARV-825 and nintedanib-loaded PEGylated nano-liposomes for synergistic efficacy in vemurafnib-resistant melanoma","volume":"13","author":"Fu","year":"2021","journal-title":"Pharmaceutics"},{"issue":"10","key":"bib135","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1167\/iovs.04-1311","article-title":"A potential role for TGF\u00df in the regulation of uveal melanoma adhesive interactions with the hepatic endothelium","volume":"46","author":"Woodward","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib136","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/OTT.S18155","article-title":"Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC","volume":"4","author":"Ballas","year":"2011","journal-title":"Onco Targets Ther"},{"issue":"10","key":"bib137","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3390\/biomedicines9101311","article-title":"New therapeutic perspectives in the treatment of uveal melanoma: a systematic review","volume":"9","author":"Toro","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"bib138","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/COC.0b013e3181d2ed67","article-title":"A pilot study of bevacizumab and interferon-a2b in ocular melanoma","volume":"34","author":"Guenterberg","year":"2011","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"bib139","doi-asserted-by":"publisher","first-page":"e48787","DOI":"10.1371\/journal.pone.0048787","article-title":"Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512","volume":"7","author":"Bhatia","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"bib140","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/CMR.0b013e328358b373","article-title":"A pilot study of sunitinib malate in patients with metastatic uveal melanoma","volume":"22","author":"Mahipal","year":"2012","journal-title":"Melanoma Res"},{"issue":"1","key":"bib141","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/bjc.2016.119","article-title":"Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study","volume":"115","author":"Mouriaux","year":"2016","journal-title":"Br J Cancer"},{"issue":"4","key":"bib142","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/bjc.2016.419","article-title":"Phase II randomised discontinuation trial of the MET\/VEGF receptor inhibitor cabozantinib in metastatic melanoma","volume":"116","author":"Daud","year":"2017","journal-title":"Br J Cancer"},{"issue":"4","key":"bib143","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/1078-0432.CCR-19-1223","article-title":"Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)","volume":"26","author":"Luke","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4 Suppl","key":"bib144","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1471-4914(02)02317-1","article-title":"HIF-1 and tumor progression: pathophysiology and therapeutics","volume":"8","author":"Semenza","year":"2002","journal-title":"Trends Mol Med"},{"issue":"7","key":"bib145","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00109-008-0337-z","article-title":"R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways","volume":"86","author":"Cao","year":"2008","journal-title":"J Mol Med (Berl)"},{"issue":"8","key":"bib146","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"bib147","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"issue":"3","key":"bib148","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"issue":"3","key":"bib149","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.drup.2009.03.002","article-title":"Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies","volume":"12","author":"Rapisarda","year":"2009","journal-title":"Drug Resist Updat"},{"issue":"1","key":"bib150","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cytogfr.2009.11.003","article-title":"Pathways mediating VEGF-independent tumor angiogenesis","volume":"21","author":"Ferrara","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"issue":"10","key":"bib151","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1182\/blood-2011-01-331694","article-title":"Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression","volume":"118","author":"Franco","year":"2011","journal-title":"Blood"},{"issue":"3","key":"bib152","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","article-title":"Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions","volume":"17","author":"Vasudev","year":"2014","journal-title":"Angiogenesis"},{"issue":"25","key":"bib153","doi-asserted-by":"publisher","first-page":"38467","DOI":"10.18632\/oncotarget.v7i25","article-title":"Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib","volume":"7","author":"Serova","year":"2016","journal-title":"Oncotarget"},{"key":"bib154","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/978-1-4939-7595-2","article-title":"Strategies to target matrix metalloproteinases as therapeutic approach in cancer","volume":"1731","author":"Piperigkou","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"5","key":"bib155","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.tibtech.2019.12.021","article-title":"Enabling technologies for personalized and precision medicine.","volume":"38","author":"Ho","year":"2020","journal-title":"Trends in Biotechnol."},{"key":"bib33","first-page":"S117","article-title":"Anti-angiogenic therapy in uveal melanoma","volume-title":"Developments in Ophthalmology","author":"el Filali","year":"2011"},{"key":"bib60","author":"European Medicines Agency"},{"key":"bib61","author":"European Medicines Agency"},{"key":"bib67","author":"ThermoFisher Scientific, Molecular Probes invitrogen detection technologies"},{"key":"bib68","author":"invitrogen, ThermoFisher Scientific"},{"key":"bib73","author":"ThermoFisher Scientific"}],"container-title":["Investigative Opthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2793386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:31:51Z","timestamp":1791927111000},"score":1,"resource":{"primary":{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2793386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":155,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.65.2.30","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}